{"id":"topical-cyclopentolate-and-phenylephrine","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient stinging or irritation"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Increased intraocular pressure"},{"rate":null,"effect":"Systemic anticholinergic effects (rare with topical use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclopentolate is an anticholinergic agent that paralyzes the ciliary muscle and dilates the pupil by blocking parasympathetic signaling. Phenylephrine is an alpha-1 adrenergic agonist that further dilates the pupil through sympathomimetic action. Together, this combination produces rapid and pronounced mydriasis and cycloplegia for diagnostic and therapeutic ophthalmic procedures.","oneSentence":"Cyclopentolate blocks muscarinic acetylcholine receptors to cause mydriasis and cycloplegia, while phenylephrine stimulates alpha-1 adrenergic receptors to enhance mydriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:17.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mydriasis and cycloplegia for ophthalmic examination and refraction"},{"name":"Mydriasis for ophthalmic diagnostic procedures"}]},"trialDetails":[{"nctId":"NCT04396301","phase":"PHASE3","title":"Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco","status":"COMPLETED","sponsor":"Cairo University","startDate":"2019-02-01","conditions":"Corneal Endothelial Cell Loss, Mydriasis, Cataract","enrollment":30},{"nctId":"NCT02909140","phase":"NA","title":"Optimal Method for Mydriasis in Cataract Surgery","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2016-09","conditions":"Cataract","enrollment":3},{"nctId":"NCT03638726","phase":"PHASE4","title":"Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification","status":"UNKNOWN","sponsor":"Dar El Oyoun Hospital","startDate":"2018-09-28","conditions":"Cataract, Mydriasis, Adverse Drug Event","enrollment":40},{"nctId":"NCT01170130","phase":"NA","title":"Lidocaine Usage for Pupil Dilatation (Mydriasis)","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2009-12","conditions":"Cataract","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclophrine eye drops"],"phase":"marketed","status":"active","brandName":"Topical cyclopentolate and phenylephrine","genericName":"Topical cyclopentolate and phenylephrine","companyName":"Dar El Oyoun Hospital","companyId":"dar-el-oyoun-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical cyclopentolate and phenylephrine are small molecule medications used to treat conditions such as cataract and corneal endothelial cell loss, and to induce mydriasis. They are administered topically and have been studied in clinical trials for their efficacy and safety in these applications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}